Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status

Corticostriatal and Dopaminergic Response to Beer Flavor with Both fMRI and [11C]raclopride Positron Emission Tomography

(2016) Brandon G. Oberlin et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype

(2016) Hisham Ziauddeen et al.   NEUROPSYCHOPHARMACOLOGY

Neural substrates of cue reactivity: association with treatment outcomes and relapse

(2015) Kelly E. Courtney et al.   ADDICTION BIOLOGY

Adolescent heavy drinkers' amplified brain responses to alcohol cues decrease over one month of abstinence

(2015) Ty Brumback et al.   ADDICTIVE BEHAVIORS

Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: A functional imaging study in alcohol dependent subjects

(2015) Patrick Bach et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A comparison of region-of-interest measures for extracting whole brain data using survival analysis in alcoholism as an example

(2015) I. Reinhard et al.   JOURNAL OF NEUROSCIENCE METHODS

Naltrexone vs Placebo for the Treatment of Alcohol Dependence

(2015) David W. Oslin et al.   JAMA Psychiatry

Naltrexone Improves Quit Rates, Attenuates Smoking Urge, and Reduces Alcohol Use in Heavy Drinking Smokers Attempting to Quit Smoking

(2014) Daniel J. Fridberg et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Predicting Naltrexone Response in Alcohol-Dependent Patients: The Contribution of Functional Magnetic Resonance Imaging

(2014) Karl Mann et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

The association between cue-reactivity in the precuneus and level of dependence on nicotine and alcohol

(2014) Kelly E. Courtney et al.   DRUG AND ALCOHOL DEPENDENCE

Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings

(2014) Daniel E. Jonas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Initial Evidence that OPRM1 Genotype Moderates Ventral and Dorsal Striatum Functional Connectivity During Alcohol Cues

(2013) Lara A. Ray et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: A bold FMRI study

(2013) Scott E. Lukas et al.   NEUROIMAGE

Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics

(2013) Joseph P. Schacht et al.   PSYCHOPHARMACOLOGY

Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects

(2012) Elise M. Weerts et al.   ADDICTION BIOLOGY

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis

(2012) Antonio-Javier Chamorro et al.   ADDICTION BIOLOGY

Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review

(2012) Joseph P. Schacht et al.   ADDICTION BIOLOGY

Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence

(2012) Lisa M. Fucito et al.   BIOLOGICAL PSYCHIATRY

Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects

(2012) Elise M. Weerts et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Interacting Effects of Naltrexone and OPRM1 and DAT1 Variation on the Neural Response to Alcohol Cues

(2012) Joseph P Schacht et al.   NEUROPSYCHOPHARMACOLOGY

[18F]fallypride PET measurement of striatal and extrastriatal dopamine D2/3 receptor availability in recently abstinent alcoholics

(2011) Axel Rominger et al.   ADDICTION BIOLOGY

Stability of fMRI striatal response to alcohol cues: A hierarchical linear modeling approach

(2011) Joseph P. Schacht et al.   NEUROIMAGE

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence

(2011) Janet K. Coller et al.   Pharmacogenetics and Genomics

Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical Trials

(2010) Daniel Falk et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

The Effect of Aripiprazole on Cue-Induced Brain Activation and Drinking Parameters in Alcoholics

(2010) Hugh Myrick et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A genetic determinant of the striatal dopamine response to alcohol in men

(2010) V A Ramchandani et al.   MOLECULAR PSYCHIATRY

Naltrexone Decreases Heavy Drinking Rates in Smoking Cessation Treatment: An Exploratory Study

(2009) Andrea King et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of thePredict Study

(2009) Karl Mann et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Family history of alcoholism mediates the frontal response to alcoholic drink odors and alcohol in at-risk drinkers

(2009) David A. Kareken et al.   NEUROIMAGE

Differential Neural Response to Alcohol Priming and Alcohol Taste Cues Is Associated With DRD4 VNTR and OPRM1 Genotypes

(2008) Francesca M. Filbey et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent People

(2008) Hugh Myrick et al.   ARCHIVES OF GENERAL PSYCHIATRY

An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence

(2008) Raymond F. Anton et al.   ARCHIVES OF GENERAL PSYCHIATRY

Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation

(2008) Stephanie S. O'Malley et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY